==Robo.ai Inc. (AIIO)

 

NWTN Inc. did not conduct a traditional public offering; instead, it went public via a merger with the SPAC East Stone Acquisition Corporation on November 14, 2022. 

In August 2025, the company officially rebranded as Robo.ai Inc. and trades on the Nasdaq under the ticker AIIO. 

The company has undergone several major strategic shifts and corporate updates: 

• Strategic Rebrand & Pivot: Formerly a new energy vehicle (NEV) specialist headquartered in Dubai, the company transitioned its focus to AI, edge processing, and robotics platforms . 
• Corporate Actions: In April 2026, the company implemented a 1-for-20 reverse stock split to maintain compliance with Nasdaq's US$1.00 minimum bid price . 
• Recent Compliance: Robo.ai received official notification from Nasdaq that it successfully regained compliance with the minimum bid price requirement . 
• Recent Acquisitions: Robo.ai finalized the 100% equity acquisition of Neurovia AI, an AI visual data compression firm . 

Zura Bio (ZURA): 3-year performance

Zura Bio, the clinical-stage immunology company entered the public markets on March 21, 2023, by completing a reverse merger with the special purpose acquisition company (SPAC) JATT Acquisition Corp.

 

Zura Bio develops therapeutic medicines for immune and inflammatory disorders, with a pipeline that includes product candidates like tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880).

• Founded 2022
• Website zurabio.com
• Employees 40
• https://zurabio.com/

IPO: March 21, 2023

===Filana Therapeutics (FLNA)

Pain Therapeutics, Inc. was a drug development company that rebranded as Cassava Sciences, Inc. in 2019. Following multiple regulatory rejections for its chronic pain drug Remoxy, the company shifted its focus to neurodegenerative diseases. In early 2026, the corporation further rebranded as Filana Therapeutics.

        

Origins (1998): Founded by Remi Barbier, the company originally focused on non-addictive pain therapies and abuse-deterrent opioids. 

Pain Programs: Its primary pipeline candidates included Remoxy (an abuse-deterrent oxycodone) and Oxytrex. After repeated Complete Response Letters (CRLs) from the FDA, the company abandoned its pain pipeline to focus on neurological conditions.

PTI-901 aimed to treat irritable bowel syndrome. 

The company had no drug approved as of 2021, and no product revenues between 2013 and 2021; with 25 employees, the company's stock was the sixth-best performing in 2021 before falling after concerns over simufilam research.

Alzheimer's Drug Failure: The biotech discontinued all trials of simufilam for Alzheimer's disease after the drug missed all primary and secondary endpoints in late-stage Phase III studies.( late 2024).

Scrutiny and Investigations: The drug and its foundational data were subject to intense scrutiny. The SEC sued the company for allegedly publishing misleading data , and a federal grand jury indicted a former scientific advisor to the company for allegedly submitting false data regarding the drug's mechanism .

Corporate Settlement & Leadership Changes: Following the data controversy, several top executives—including former CEO Remi Barbier—resigned. Under new CEO Richard Barry, Cassava paid a $40 million fine to the SEC to settle misleading claims , and the DOJ subsequently closed its probe.

The company initially worked on three drugs: the pain drugs Oxytrex and Remoxy, and 

The Pivot to Filana Therapeutics: Shedding its troubled past, the company officially changed its name to Filana Therapeutics in March 2026. The biotech now trades under the ticker symbol "FLNA" and has shifted its developmental focus toward central nervous system (CNS) disorders, specifically exploring simufilam as a potential treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy.

==Uber-backed Lime has filed for an IPO

Lime, founded ‌in 2017 and helmed by former Uber executive Wayne Ting, operated in about 230 cities across 29 countries, as of December 31, 2025.

Lime, which ⁠provides short-term rentals of electric bikes and scooters, and some selling shareholders are looking to sell about 6.96 million shares in total, priced between $24 and $26 apiece, aiming to raise ‌up to $181.9 million.

Key Details:

• Ticker: LIME (planned for Nasdaq)
• Price range: $24–$26 per share
• Shares offered: ~6.96 million total (mostly by the company, some by selling shareholders)
• Expected raise: Up to ~$182 million (at midpoint)
• Valuation: Targeting up to ~$1.66–1.8 billion (post-IPO)
• Underwriters: Led by Goldman Sachs and JPMorgan
• Roadshow: Launched around June 22, 2026; pricing expected the week of June 29, 2026 (trading shortly after)

The firm outlined in its prospectus that ⁠it has incurred net losses in every year since its inception. For 2025, it posted a net loss of $59.3 million ​on revenue of $886.7 million.

The company, which filed for its public offering last month, has applied to list on the ​Nasdaq under the ticker symbol “LIME.”

Goldman Sachs, ‌J.P. Morgan and Jefferies are among the underwriters for the offering. ​

Legend Biotech (LEGN) prices offering of 7.7 mln ADSs at $29.35 per ADS

• Legend Biotech prices 7.7 million ADS underwritten offering at $29.35 each for expected gross proceeds of approximately $226 million
•  Legend Biotech (NASDAQ: LEGN) went public on June 5, 2020, raising approximately $424 million in its initial public offering (IPO). The company originally offered 18.4 million American Depositary Shares (ADS) at a price of $23.00 per share.
• https://legendbiotech.com/

---Aerospace parts maker Doncasters targets $4.4 billion valuation in US IPO

June 15 (Reuters) - Doncasters is targeting a valuation of up to $4.43 billion in its U.S. initial public offering, ​becoming the latest aerospace firm to test investor appetite for new ‌listings.

The Derby, United Kingdom-based company is seeking up to $746.7 million in the IPO by offering 23.3 million shares priced between $28 and $32 apiece, it said on Monday.

Ticker: DPC

Exchange: NYSE

Target Deal Size: ~ $700 million

Share Price Range: $28 to $32

Target Valuation: Up to $4.43 billion at the high end of the range

Lead Bookrunners: Jefferies and Morgan Stanley

The U.S. IPO market ​has gained momentum after a choppy start to the year, with aerospace ​and defense as well as AI infrastructure themes dominating the ⁠lineup since April.

Doncasters will follow Arxis (ARXS.O), opens new tab and Applied Aerospace & Defense (AADX.N), opens new tab, fellow aerospace parts ​makers that have gone public in New York since April.

Company Overview

• History: Founded in 1778 in Sheffield, UK, the company manufactures high-precision alloy components (like turbine blades and vanes) for the "hot zones" of aerospace engines and industrial gas turbines. 
• Clients: Serves major original equipment manufacturers (OEMs) including GE Aerospace, Honeywell, Pratt & Whitney, and Rolls-Royce. 
• Financials: In 2025, the company reported revenue of $837 million, though it remains loss-making due to heavy investments in expanding capacity. 

Orion S.A. (OEC) : 12-year performance

Orion S.A. (NYSE: OEC), a global specialty chemical company and leading carbon black producer, completed its Initial Public Offering on July 25, 2014. The company raised roughly $350 million, pricing its shares at $18 each. 

• Sector: Basic Materials
• Industry: Specialty Chemicals
• Full Time Employees: 1,639
• Founded in 1862 
• Headquartered in Senningerberg, Luxembourg.
• https://www.orioncarbons.com

IPO Details

• Ticker Symbol: OEC (New York Stock Exchange)
• IPO Date: July 25, 2014
• Shares Offered: 19.5 million common shares
• Initial Pricing: $18.00 per share
• Lead Underwriters: The primary selling shareholders were Kinove Luxembourg Holdings 1 S.à r.l. and affiliates of private equity firms Triton and Rhone Group. 

The stock experienced historical highs near $32.61 in 2018.

===Quantinuum (QNT) began trading on the Nasdaq on Thur 4 June 26

 

Quantinuum is the world’s largest integrated quantum computing company, formed in late 2021 by the merger of Honeywell Quantum Solutions (hardware expertise, trapped-ion technology) and Cambridge Quantum (software, algorithms, and quantum cybersecurity).Key Facts

• Headquarters: Broomfield, Colorado (US), with major operations in Cambridge, UK, and additional sites in Germany, Japan, and elsewhere.
• Employees: Approximately 450–680 (sources vary; includes 370+ scientists and engineers, with a high proportion holding advanced degrees).
• Leadership: CEO Rajeeb Hazra; Ilyas Khan (founder of Cambridge Quantum) serves as Chief Product Officer.
• Status: Privately held until recently; it completed a major IPO in early June 2026 on Nasdaq (ticker QNT), raising significant capital at a multi-billion-dollar valuation amid strong demand. Honeywell remains a major backer.

TechnologyQuantinuum specializes in trapped-ion quantum computers, widely regarded as among the highest-performing in the industry due to high gate fidelities, full qubit connectivity, and support for mid-circuit measurements.

• H-Series (e.g., System Model H2): Features up to 56 fully connected qubits, record quantum volumes (a holistic performance metric exceeding 2 million in some reports), and >99.99% single-qubit gate fidelity. It has demonstrated milestones like the first fully fault-tolerant universal gate set.
• Roadmap: Accelerated push toward universal, fault-tolerant quantum computing by 2030, with next-generation systems like Apollo (targeting 100+ qubits). Emphasis on scalable, high-fidelity hardware combined with error correction.
• Software & Full-Stack: Includes TKET (open-source compiler), InQuanto (chemistry-focused), Quantum Origin (quantum-enhanced cybersecurity/randomness), and the Nexus platform for cloud access, emulation, and hybrid workflows. Strong integration across hardware, software, and applications.

Access is available via cloud (e.g., Azure Quantum) and direct subscriptions, with emulators for development.

Applications and Focus AreasThe company targets commercial and scientific breakthroughs in:

• Materials discovery and computational chemistry
• Drug discovery and biology
• Cybersecurity (quantum-resistant solutions)
• Optimization, AI, finance, and energy (e.g., collaborations with bp on wave physics/seismic imaging)
• Hybrid quantum-classical computing for industry use cases

It emphasizes "science-led, enterprise-driven" solutions and has partnerships with entities like RIKEN, Mitsubishi Electric, NVIDIA, JPMorgan, Synopsys, and others.